Cost-Effectiveness Analysis of Cefoperazone Sodium/Sulbactam Sodium vs. Levofloxacin in the Treatment of Community Acquired Pneumonia

OBJECTIVE:To evaluate the cost-effectiveness of two therapeutic schemes in the treatment of community acquired pneumonia.METHODS:A retrospective study was conducted in which a total of 88 cases with community acquired pneumonia were randomly assigned to receive cefoperazone sodium/sulbactam sodium(Group A) or levofloxacin(Group B).The therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the two group.RESULTS:The cost was 1 803.91 yuan in Group A versus 1 599.81 yuan in Group B(P0.05);the effective rates were 95.0% versus 100.0%(P0.05) and the cost-effectiveness ratios were 1 898.85 and 1 599.81,respectively.CONCLUSION:Levoflocaxin is superior to cefoperazone sodium/sulbactam sodium for community acquired pneumonia.